🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareInsurance denied my prior auth — successful appeal letter template Page 2

Insurance denied my prior auth — successful appeal letter template

InsuranceTom Mon, Apr 20, 2026 at 11:11 AM 9 replies 565 viewsPage 2 of 2
hank_denver
Member
278
1,234
Sep 2024
Denver, CO
Apr 20, 2026 at 1:55 PM#6
InsuranceTom said:
Denials are usually procedural rather than clinical, and the order that works reflects that.
InsuranceTom said:
...my insurance denied cost and coverage coverage because...

Insurance denial is the single biggest barrier to GLP-1 access. Let me share the appeal framework that worked for me and several community members:

  1. Document medical necessity (BMI, comorbidities, failed alternatives)
  2. Reference clinical practice guidelines (AGA, AACE, Endocrine Society)
  3. Cite cost-effectiveness data (preventing diabetes/surgery saves money long-term)
  4. Request peer-to-peer review between your doctor and the plan's medical director
  5. File external appeal with your state insurance department if internal appeal fails

Don't accept the first denial. The appeal process exists for a reason.

Last edited: Apr 20, 2026 at 5:55 PM
14 9ingrid_STO, pete_nash, hank_denver and 11 others
Reply Quote Save Share Report
emily_PDX
Member
245
1,123
Nov 2024
Portland, OR
Apr 20, 2026 at 2:59 PM#7

Following on from Dr.AddMedPHL — and this may be the naive question:

Did your prescriber agree with that reading, and if not what was their objection?

Last edited: Apr 20, 2026 at 4:59 PM
13 8PharmD_Rodriguez, julia.endo, JessicaM_2024 and 10 others
Reply Quote Save Share Report
Dr.EndoIndy
Member
267
1,234
Oct 2024
Indianapolis, IN
Apr 20, 2026 at 4:03 PM#8
hank_denver said:
InsuranceTom said: ...my insurance denied cost and coverage coverage because...
hank_denver said:
...regarding the discontinuation data for cost and coverage...

I want to reframe the discontinuation narrative. We don't say "insulin fails because blood sugar rises when you stop it." We don't say "antihypertensives fail because BP goes up without them."

Why do we apply different logic to anti-obesity medications? The answer is stigma. We still, unconsciously, believe obesity is about willpower rather than biology. The discontinuation data actually PROVES it's a chronic biological condition requiring ongoing treatment.

This reframing isn't semantic — it has implications for insurance coverage, treatment duration, and patient expectations.

12 7marcus_mpls, DeniseRN_TPA, SandraNC_45 and 9 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
InsuranceTom
Senior Member
1,345
7,890
Mar 2024
Connecticut
Apr 20, 2026 at 5:07 PM#9

Reporting back.

Update: approved on the third attempt after a peer-to-peer. Nothing about my case changed; only who was doing the talking.

Last edited: Apr 20, 2026 at 10:07 PM
11 6matt_MKE, Dr.ReproEndo, lucas_SP_BR and 8 others
Reply Quote Save Share Report
RegAffairsDC
Member
678
3,456
May 2024
Washington, DC
Apr 20, 2026 at 10:17 PM#10
Dr.EndoIndy said:
hank_denver said: ...regarding the discontinuation data for cost and coverage...

Insurance update relevant to cost and coverage: I just got my prior auth approved through Blue Cross after 3 attempts.

What finally worked: a letter from my endocrinologist documenting BMI history (>3 years), failed diet attempts, comorbidities (sleep apnea + prediabetes), and referencing the SURMOUNT trial data.

If your PA keeps getting denied, don't give up. Request a peer-to-peer review between your doctor and the insurance medical director. That's what finally broke through for me.

37 10gary_naperville, sean_dublin, hannah_MT and 34 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register